Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Lancet Oncology

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(15)00004-2PMID 26187751PMCID PMC4670237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

  2014cited by this paper
• Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome

  2014cited by this paper
• Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.

  2014cited by this paper
• Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes

  2014cited by this paper
• The Clavien–Dindo Classification of Surgical Complications

  2014cited by this paper
• Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients.

  2013cited by this paper
• Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial

  2013cited by this paper
• Impact of Interval between Neoadjuvant Chemoradiotherapy and TME for Locally Advanced Rectal Cancer on Pathologic Response and Oncologic Outcome

  2012cited by this paper
• Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

  2012cited by this paper
• Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).

  2012cited by this paper
• Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

  2012cited by this paper
• Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy

  2012cited by this paper
• Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

  2012cited by this paper
• Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.

  2012cited by this paper
• Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.

  2011cited by this paper
• Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

  2011cited by this paper
• Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer Decreases Distant Recurrence and Could Eradicate Local Recurrence

  2011cited by this paper
• Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

  2010cited by this paper
• Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

  2010cited by this paper
• Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer d

  2010cited by this paper
• The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience

  2009cited by this paper
• Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer

  2009cited by this paper
• An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease–Free Survival in Patients with Locally Advanced Rectal Cancer

  2008cited by this paper
• Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?

  2008cited by this paper
• Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis

  2008cited by this paper
• Recommendations for the reporting of surgically resected specimens of colorectal carcinoma.

  2007cited by this paper
• Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer

  2006cited by this paper
• Recommendations for the reporting of surgically resected specimens of colorectal carcinoma

  2006cited by this paper
• Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation.

  2006cited by this paper
• The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer

  2005cited by this paper
• Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-term Results

  2004cited by this paper
• Preoperative versus postoperative chemoradiotherapy for rectal cancer.

  2004cited by this paper
• Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection

  2004cited by this paper
• Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.

  1999cited by this paper
• Adenocarcinoma of the rectum treated by radical external radiation therapy.

  1995cited by this paper
• The quality of life after rectal excision for low rectal cancer

  1983cited by this paper

• Organ preservation in rectal cancer: an endoscopist's perspective on current evidence and future directions.

  2026cites this paper
• Impact of prolonged interval between neoadjuvant chemoradiotherapy and surgery on outcomes in locally advanced rectal cancer: A systematic review and meta-analysis

  2026cites this paper
• Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting

  2026cites this paper
• Can We Predict Which Patients with Rectal Cancer Will Have a Complete Response to Neoadjuvant Therapy?

  2026cites this paper
• Local Tumor Regrowth after Nonoperative Management Following Neoadjuvant Therapy for Rectal Cancer

  2026cites this paper
• Gastrointestinal Toxicity and Clinical Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Real-World Retrospective Study

  2026cites this paper
• Emergency rectal cancer: clinical presentation and therapeutic options

  2026cites this paper
• Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.

  2026cites this paper
• Clinical and treatment-related predictors of complete response after total neoadjuvant therapy for rectal cancer in a large multicenter analysis

  2026cites this paper
• Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.

  2026cites this paper
• Strategia oncochirurgica di gestione delle metastasi epatiche di origine colorettale

  2025cites this paper
• Sciatic Nerve Preservation in Robot‐Assisted Surgery for Initially Unresectable Primary Rectal Cancer: A Case Report

  2025cites this paper
• Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer

  2025cites this paper
• Organ preservation via immunotherapy-based total neoadjuvant therapy in early low rectal cancer (TORCH-E): a multicenter, open-label, single-arm, phase 2 study.

  2025cites this paper
• Interpretable machine learning model for predicting perioperative Clavien-Dindo III/IV complications of rectal cancer anterior resection after neoadjuvant therapy: a real-world study.

  2025cites this paper
• Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorithm.

  2025cites this paper
• Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II).

  2025cites this paper
• Distant Metastases With Nonoperative Management in Rectal Cancer: Challenges in Defining Risk.

  2025cites this paper
• Evaluation of the effectiveness of using capecitabine versus capecitabine combined with oxaliplatin during preoperative radiotherapy for patients with rectal cancer: A retrospective cohort study

  2025cites this paper
• Total neoadjuvant therapy for locally advanced rectal cancer

  2025cites this paper
• Results of radical treatment of locally advanced rectal cancer in geriatric and non-geriatric patients

  2025cites this paper
• Early Rectal Cancer: Advances in Diagnosis and Management Strategies

  2025cites this paper
• Multimodal Preoperative Management of Rectal Cancer: A Review of the Existing Guidelines

  2025cites this paper
• Compliance and Toxicity of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Predictive Value of Magnetic Resonance Complete Response After Neoadjuvant Therapy for Rectal Cancer.

  2025cites this paper
• Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

  2025cites this paper
• Neoadjuvant Treatment for Locally Advanced Rectal Cancer: Current Status and Future Directions

  2025cites this paper
• Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer

  2025cites this paper
• Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series.

  2025cites this paper
• Short-course radiotherapy versus long-course chemoradiotherapy in total neoadjuvant therapy of rectal cancer - A multicenter analysis of early outcomes and toxicity.

  2025cites this paper
• Impact of PD1 blockade added to neoadjuvant chemoradiotherapy on rectal cancer surgery: post-hoc analysis of the randomized POLARSTAR trial.

  2025cites this paper
• Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer

  2025cites this paper
• MRI-defined high-risk rectal cancer patients: comparison of treatment response and survival outcomes between total neoadjuvant therapy and neoadjuvant chemoradiotherapy—a propensity score matched analysis

  2025cites this paper
• Mastering rectal cancer MRI: From foundational concepts to optimal staging.

  2025cites this paper
• Why Is There a Demand for Organ-Sparing Approaches in the Era of TNT and TME?

  2025cites this paper
• International expert Delphi consensus on management of early and locally advanced rectal cancer

  2025cites this paper
• Quality of life and functional outcomes in patients with locally advanced rectal cancer receiving total neoadjuvant therapy versus concurrent chemoradiotherapy: An analysis of the XXX trial.

  2025cites this paper
• Curative-Intended Management of Synchronous Esophageal and Rectal Cancer—A Systematic Literature Review

  2025cites this paper
• Perineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial

  2025cites this paper
• Real-world clinical outcomes of total neoadjuvant therapy followed by total mesorectal excision for locally advanced rectal cancer at a high-volume institution.

  2025cites this paper
• Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis

  2025cites this paper
• Utilizing Patient Input in Rectal Cancer Trial Design.

  2025cites this paper
• Evaluating the Impact of Induction and Consolidation Total Neoadjuvant Therapies Compared to Conventional Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Is clinical complete response as accurate as pathological complete response in patients with mid-low locally advanced rectal cancer?

  2025cites this paper
• MRI is more accurate than FDG-PET in assessing complete response in rectal cancer patients after neoadjuvant therapy

  2025influential citation
• Comparison of prognosis for T4b rectal cancer with different pelvic compartment involvement treated using neoadjuvant chemoradiotherapy and implications for refinement of the current T staging system: A retrospective cohort study

  2025cites this paper
• Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.

  2025cites this paper
• Personalized surveillance in colorectal cancer: Integrating circulating tumor DNA and artificial intelligence into post-treatment follow-up

  2025cites this paper
• Comparing early surgical outcomes between total neoadjuvant therapy and standard long course chemoradiotherapy for rectal cancer

  2025cites this paper
• Watch and wait in locally advanced rectal cancer: Evolution, current evidence, and future directions

  2025cites this paper
• "Watch-and-wait" or "Lost to Follow-up"? Adherence to Nonoperative Management of Rectal Cancer.

  2025cites this paper
• Total neoadjuvant therapy integrating long-course radiotherapy with trifluridine/tipiracil for locally advanced rectal cancer: a single-arm, multicenter phase 2 trial

  2025cites this paper
• Stratégie oncochirurgicale de prise en charge des métastases hépatiques d’origine colorectale

  2025cites this paper
• Partial Responders to Neoadjuvant Therapy and the Risk of Distant Metastases: Longer Intervals to Definitive Resection Is Not a Risk Factor.

  2025cites this paper
• A Comprehensive Approach to Neoadjuvant Treatment of Locally Advanced Rectal Cancer

  2025cites this paper
• The Shifting and Evolving Neoadjuvant Treatments and Surgical Platforms on Oncological Outcomes and Sphincter Preservation in Distal Rectal Cancer: A 23-Year Retrospective Experience

  2025cites this paper
• Assessment of response to total neoadjuvant therapy in carcinoma rectum: A real-world prospective observational study from eastern India.

  2025cites this paper
• Pre-operative Radiotherapy in Locally Advanced Breast Cancer: A Narrative Review.

  2025cites this paper
• Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis

  2025cites this paper
• Safety and efficacy of individualized modified total neoadjuvant therapy for low locally advanced rectal cancer

  2025cites this paper
• Estrategia oncoquirúrgica para el manejo de las metástasis hepáticas de origen colorrectal

  2025cites this paper
• Preoperative MRI assessment of rectal cancer for predicting metastasis-free survival-a post hoc analysis of a randomized controlled clinical trial.

  2025cites this paper
• Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2025cites this paper
• The Landmark Series: Organ Preservation in Rectal Cancer—The Watch and Wait Strategy

  2025cites this paper
• Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.

  2024cites this paper
• Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma

  2024cites this paper
• NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

  2024cites this paper
• Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer

  2024cites this paper
• Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer

  2024cites this paper
• Nonoperative Management for Rectal Cancer

  2024cites this paper
• Evaluating Complete Response Rates and Predictors in Total Neoadjuvant Therapy for Rectal Cancer.

  2024cites this paper
• Outcomes associated with total neoadjuvant therapy with non-operative intent for rectal adenocarcinoma

  2024cites this paper
• Point/Counterpoint #2

  2024cites this paper
• Significance of MRI-based radiomics in predicting pathological complete response to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A narrative review.

  2024cites this paper
• Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy

  2024cites this paper
• Oncological Outcomes and Response Rate After Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Network Meta-Analysis Comparing Induction vs. Consolidation Chemotherapy vs. Standard Chemoradiation.

  2024cites this paper
• Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use?

  2024cites this paper
• Pathologic Outcomes of Short-Course and Long-Course Radiotherapy for Locally Advanced Rectal Cancers Treated With Total Neoadjuvant Therapy

  2024cites this paper
• ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer

  2024cites this paper
• Executive Summary of the American Radium Society® (ARS) Appropriate Use Criteria (AUC) for Non-Operative Management (NOM) for Rectal Adenocarcinoma: Systematic Review and Guidelines.

  2024cites this paper
• Implementing a no-drain policy for extraperitoneal colorectal anastomosis in a real-life setting: analysis of outcomes and surgeons’ adherence

  2024cites this paper
• A dynamic nomogram for predicting pathologic complete response to neoadjuvant chemotherapy in locally advanced rectal cancer

  2024cites this paper
• Journey through the Decades: The Evolution in Treatment and Shared Decision Making for Locally Advanced Rectal Cancer

  2024cites this paper
• Imaging Assessment of the Response to Neoadjuvant Treatment in Rectal Cancer in Relation to Postoperative Pathological Outcomes

  2024cites this paper
• Rectal cancer survival and prognostic factors in Iranian population: A retrospective cohort study.

  2024cites this paper
• Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer.

  2024cites this paper
• Four steps in the evolution of rectal cancer managements through 40 years of clinical practice: pioneering, standardization, challenges and personalization.

  2024cites this paper
• Influence of neoadjuvant treatment strategy on perioperative outcomes in locally advanced rectal cancer

  2024cites this paper
• Future direction of total neoadjuvant therapy for locally advanced rectal cancer

  2024cites this paper
• Neoadjuvant Short- Vs. Long-Course Radiation for Locally Advanced Rectal Cancer: How to Choose

  2024cites this paper
• Total Neoadjuvant Therapy for Rectal Cancer.

  2024cites this paper
• Recent advances in rectal cancer treatment – are we on the right track?

  2024cites this paper
• Assessing the OPRA Trial for surgical oncologists: Safety and feasibility of a total neoadjuvant therapy approach in patients with rectal cancer.

  2024cites this paper
• Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study

  2024influential citation
• Combinatorial Approaches for Chemotherapies and Targeted Therapies with Radiation: United Efforts to Innovate in Patient Care.

  2024cites this paper
• Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0–1 disease treated with upfront surgery

  2024cites this paper
• Retrospective Evaluation of the Efficacy of Total Neoadjuvant Therapy and Chemoradiotherapy Neoadjuvant Treatment in Relation to Surgery in Patients with Rectal Cancer

  2024cites this paper
• Discovery of Oncogenic Mediator Genes in Rectal Cancer Chemotherapy Response using Gene Expression Data from Matched Tumor and Patient-Derived Organoid

  2024cites this paper
• Quality of life and clinical outcomes in rectal cancer patients treated on a 1.5T MR-Linac within the MOMENTUM study

  2024cites this paper
• Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy

  2024cites this paper